Current Report Filing (8-k)
February 19 2020 - 8:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 19, 2020
resTORbio, Inc.
(Exact
name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-38359
|
|
81-3305277
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
500 Boylston Street, 13th Floor
Boston, MA
|
|
02116
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area
code: (857) 315-5528
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.0001 per share
|
|
TORC
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01.
|
Regulation FD Disclosure.
|
resTORbio, Inc. (the Company) from time to time presents and/or distributes to the investment community at various industry and other conferences
slide presentations to provide updates and summaries of its business. A copy of its current corporate slide presentation is furnished herewith as Exhibit 99.1 and incorporated herein by reference. The Company undertakes no obligation
to update, supplement or amend the materials furnished herewith as Exhibit 99.1.
On February 19, 2020, the Company announced interim results for its Phase 1b/2a trial of RTB101 in patients with Parkinsons disease and provided a
corporate update. A copy of the press release is filed herewith as Exhibit 99.2 and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
Date: February 19, 2020
|
|
resTORbio, Inc.
|
|
|
|
|
|
By:
|
|
/s/ Chen Schor
|
|
|
|
|
Chen Schor
|
|
|
|
|
President and Chief Executive Officer
|
resTORbio (NASDAQ:TORC)
Historical Stock Chart
From Mar 2024 to Apr 2024
resTORbio (NASDAQ:TORC)
Historical Stock Chart
From Apr 2023 to Apr 2024